ANTONIO DA SILVA COELHO NETTO, M.D.; BERNARDO LÉO WAJCHENBERG, M.D.; CASSIO RAVAGLIA, M.D.; VIRGILIO GONÇALVES PEREIRA, M.D.; JOSÉ SHNAIDER, M.D.; ARMANDO AGUIAR PUPO, M.D.; ANTONIO BARROS DE ULHOA CINTRA, M.D., PH.D.
The initial observations of Nelson and Woodward (1, 2) that the feeding of the insecticide, 1,1-dichloro-2,2-bis (p-chlorophenyl) ethane (DDD) to dogs results in necrosis and atrophy of the adrenal cortex opened a new research field for adrenocorticolytic drugs. Brown et al. (3-5) observed that necrosis of the adrenal cortex was followed by a decrease in urinary excretion of 17-hydroxycorticosteroids. In these animals a picture compatible with adrenocortical insufficiency developed which was not modified by the simultaneous administration of adrenocorticotropic hormone (ACTH) but which could be prevented by cortisone.
Other authors (6-8) confirmed these initial data and the technical grade DDD
DA SILVA COELHO NETTO A, WAJCHENBERG BL, RAVAGLIA C, et al. Treatment of Adrenocortical Cancer with O,P′-DDD. Ann Intern Med. 1963;59:74–78. doi: 10.7326/0003-4819-59-1-74
Download citation file:
Published: Ann Intern Med. 1963;59(1_Part_1):74-78.
Adrenal Disorders, Endocrine and Metabolism, Endocrine Cancer, Hematology/Oncology.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use